Wang, Joy Y.
Hoel, Christopher M. http://orcid.org/0000-0002-1344-0780
Al-Shayeb, Basem
Banfield, Jillian F. http://orcid.org/0000-0001-8203-8771
Brohawn, Stephen G. http://orcid.org/0000-0001-6768-3406
Doudna, Jennifer A. http://orcid.org/0000-0001-9161-999X
Funding for this research was provided by:
National Science Foundation (1817593)
University of California, Berkeley Graduate Fellowship
New York Stem Cell Foundation
Howard Hughes Medical Institute
Article History
Received: 30 October 2020
Accepted: 26 March 2021
First Online: 6 May 2021
Competing interests
: The Regents of the University of California have patents issued and pending for CRISPR technologies on which J.A.D. is an inventor. J.A.D. is a cofounder of Caribou Biosciences, Editas Medicine, Scribe Therapeutics, Intellia Therapeutics, and Mammoth Biosciences. J.A.D. is a scientific advisory board member of Caribou Biosciences, Intellia Therapeutics, eFFECTOR Therapeutics, Scribe Therapeutics, Mammoth Biosciences, Synthego, Algen Biotechnologies, Felix Biosciences, and Inari. J.A.D. is a Director at Johnson & Johnson and Tempus and has research projects sponsored by Biogen, Pfizer, AppleTree Partners, and Roche. The remaining authors declare no competing interests.